Quick Answer
SANGAMO THERAPEUTICS, INC reported Stockholders Equity of -$14.27 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -162.7% in Stockholders Equity from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $91.61 million | Q3 2011: $84.17 million | Q1 2012: $74.34 million | Q2 2012: $70.23 million | Q3 2012: $66.40 million | Q1 2013: $61.59 million | Q2 2013: $59.38 million | Q3 2013: $126.14 million | Q1 2014: $217.43 million | Q2 2014: $214.36 million | Q3 2014: $210.14 million | Q1 2015: $207.49 million | Q2 2015: $199.94 million | Q3 2015: $203.56 million | Q1 2016: $179.41 million | Q2 2016: $160.02 million | Q3 2016: $143.84 million | Q1 2017: $125.68 million | Q2 2017: $194.04 million | Q3 2017: $186.65 million | Q1 2018: $182.37 million | Q2 2018: $387.87 million | Q3 2018: $379.91 million | Q1 2019: $328.50 million | Q2 2019: $445.13 million | Q3 2019: $419.09 million | Q1 2020: $394.29 million | Q2 2020: $511.46 million | Q3 2020: $521.41 million | Q1 2021: $470.36 million | Q2 2021: $445.46 million | Q3 2021: $406.02 million | Q4 2021: $375.34 million | Q1 2022: $334.52 million | Q2 2022: $318.28 million | Q3 2022: $309.15 million | Q1 2023: $335.61 million | Q2 2023: $233.64 million | Q3 2023: $134.92 million | Q1 2024: $56.70 million | Q2 2024: $23.69 million | Q3 2024: $39.13 million | Q1 2025: $4.91 million | Q2 2025: $19.60 million | Q3 2025: $6.24 million.
- Over the full 18 years of available data (2008 to 2025), SANGAMO THERAPEUTICS, INC's Stockholders Equity has declined by 125.8%.
- Historical annual values: Fiscal year 2025: -$14.27 million | Fiscal year 2024: $22.77 million | Fiscal year 2023: $82.89 million | Fiscal year 2022: $294.96 million | Fiscal year 2021: $375.34 million | Fiscal year 2020: $498.23 million | Fiscal year 2019: $432.55 million | Fiscal year 2018: $366.52 million | Fiscal year 2017: $187.90 million | Fiscal year 2016: $136.20 million | Fiscal year 2015: $192.44 million | Fiscal year 2014: $206.63 million | Fiscal year 2013: $121.71 million | Fiscal year 2012: $64.90 million | Fiscal year 2011: $80.13 million | Fiscal year 2010: $55.91 million | Fiscal year 2009: $71.78 million | Fiscal year 2008: $55.40 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: